Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
this one is done, stock is worthless
Injex: insolvency proceedings (in german): there was a fault in reference link, take this one: http://www.hww.eu/de/insolvenzverwalter/insolvenzverfahren >click on "Verfahrensdaten" (hww wienberg wilhelm) >put in "Injex" in search box, click on "suchen" (search)
there was a "Sales Director", Mr. Sylwin Grinman, former responsible for USA-transactions of Injex AG, the last CEO fired him, according to what I have heard from stockholders' meeting (folk memory), greetz
reference: http://www.businesswire.com/news/home/20120904006041/en/INJEX-Pharma-AG-signs-exclusive-Distribution-Agreement#.VYv7xHrtmko
Injex: insolvency proceedings (in german): https://www.glaeubigerinfo.de/winsolvenz/gis.web/frm_Verfahrensinfo.asp?vn=459614
liquidator/bankruptcy trustee: Rüdiger Wienberg, att. reference: http://www.hww.eu/de/insolvenzverwalter/insolvenzverfahren
Have you guys heard anything about the US arm of INJEX doing business with VMGI?
I was able to connect the two companies through some DD and names etc.
"application: request of Injex Pharma AG,
Register Court: Charlottenburg, Commercial Register No .: HRB 110828
Buckower Damm 114, 12349 Berlin,
legally represented by the Board Dr. Thomas Klaue,
- Debtor -
the opening of insolvency proceedings over the assets of their own"
(trans.)
"In dem Verfahren über den Antrag d.
Injex Pharma Aktiengesellschaft,
Registergericht: Amtsgericht Charlottenburg, Handelsregister, Register-Nr.: HRB 110828
Buckower Damm 114, 12349 Berlin,
gesetzlich vertreten durch den Vorstand Dr. Thomas Klaue,
- Schuldnerin -
auf Eröffnung des Insolvenzverfahrens über das eigene Vermögen"
reference: https://www.unternehmensregister.de/ureg/result.html;jsessionid=1C38EA853EC4587A3D552BF92547EB7A.web01-1?submitaction=showDocument&id=14671355
It was a lot of fuss about nothing...
wasn't it? >IMHO
Best,
Wes
files for bankruptcy (file number: 36i IN 781/15 district court Charlottenburg) reference: 02/13/2015: https://www.unternehmensregister.de/ureg/result.html;jsessionid=1C38EA853EC4587A3D552BF92547EB7A.web01-1?submitaction=showDocument&id=14671355
well... there goes the "competitor"...
They were never a competition.
Medac is
this is kind of *busted flush*
just hyped advertisements, empty promises, for all these yrs., since issuers on the new market, suckers...
shaking my head
>IMHO
and this kind of folks craved attention in Antares Pharma board "competitor fear" lol, hahahahahahaha, busted flush .-)
>IMHO
well, rymankoly, the rats are leaving...? deserting the sinking ship.. LMAO, no thread mod(s), no listing, no share price, no Andy CEO anymore, no / inconclusive business figures, unsurprisingly
LOL, well, March 23, 2014, 1 yr. later still no listing, as expected .-)
and all thread moderators gone - LMAO^^
well, Rymankoly, good for Antares shareholders, seems they have nothing to fear from the "competitor"
(IMHO) greetz!
gone like the CEO!? LOL! Antares competitor?? That's whack!
(IMHO) greetz
What the dickens makes him tick? Antares Pharma "competitor"!?
looks like this poster is long gone....
"Andy Rösch, the founder and CEO to date, will retire at the end of June 2013"
reference: http://finance.yahoo.com/news/injex-pharma-ag-announces-changes-094300109.html
oh no! and now the "Injex" CEO (Rosch) resigned!? oh dear! Antares Pharma "competitor"!? LOL what a hoot .-)
(IMHO) greetz!
no reference for that kind of statements? well, I thought as much! .-)
Large investors are planning acquisition of 40% of all shares.
3/18 listing failed what went wrong?
Listing expected on March 18, 2013
http://www.injex.com/share-prospectus-approved
INJEX share prospectus approved by the German Federal Financial Supervisory Authority (BaFin)
Berlin, February 26, 2013 - INJEX Pharma AG is pleased to announce that the German Federal Financial Supervisory Authority (BaFin) today approved the share prospectus of the company. The prospectus is from now on available on the Company's website at www.injex.com.
watch pdf file here: Wertpapierprospekt INJEX Pharma AG
INJEX Pharma aims to achieve a listing on the regulated market of the Frankfurt Stock Exchange (segment General Standard) – an approved prospectus by BaFin is a precondition. A stock exchange listing on the regulated market is delivering increased visibility on the capital markets for the company and is part of the implementation of the growth strategy. The desired listing in General Standard will broaden the shareholder base of the company even more and will make it easier to trade the shares for international investors.
The admission of shares is expected on March 11, 2013 in the regulated market of the Frankfurt Stock Exchange in the General Standard segment. The listing is expected on March 18, 2013. A change of this timetable is still possible. The securities code number of the shares is ISIN: DE000A0STYL7, the WKN number is WKN: A0STYL.
For further information on INJEX Pharma AG and its subsidiaries, please refer to www.injex.com.
For further questions please contact our Investor Relations team directly:
INJEX Pharma AG
Investor Relations Team
t: +49 89 24 41 18 - 223
f: +49 89 24 41 18 - 499
ir@injex.com
Today, Sammy Sosa visited Injex Pharma in Berlin...
http://www.injex.de/sammy-sosa-besucht-injex-zentrale
INJEX Pharma AG doubled the office space in the Tristan Building at Buckower Damm 114. Further employees are engaged at this days. The new reception can be found on the second floor
http://www.injex.com/injex-pharma-ag-doubled-office-space
Injex21 => New distributor & website!
www.injex21.com
Quote taken from the website, as well as the grafic:
INJEX signs exclusive distributor contract for Russia
http://www.dgap.de/news/corporate/injex-pharma-signs-exclusive-distributor-contract-for-russia-with-medici-ltd-injex-systems-and-shireen-beauty-kits-the-first-year_42269_735140.htm
INJEX Pharma AG signs exclusive distributor contract for Russia with MEDICI Ltd. / 30,000 INJEX 30 Systems and 7,000 SHIREEN Beauty Kits in the first year
INJEX Pharma AG ISIN: DE000A0STYL7
Berlin, 09. October 2012
Berlin - INJEX Pharma AG, located in Berlin, has signed an exclusive distributor agreement for sales of the needle free syringe INJEX 30 Systems and new Poring-Method with the SHIREEN Beauty Kit with MEDICI Ltd., based in the World Trade Center in Moscow, Russia.
The contract contains a minimum quantity commencing in year one with a minimum of 30,000 INJEX 30 Systems and 7,000 SHIREEN Beauty Kits.
'We are excited to enter Russia with MEDICI Ltd. Russia has tremendous demand for our technology. The initial shipment of 4,000 INJEX 30 Systems and 700 SHIREEN Beauty Kits was triggered by MEDICI Ltd. meeting specific financial and logistical contractual obligations.
We have strategically defined our roll-out for INJEX. The syringe without a needle technology offers a safe and soft alternative for various medical applications including the treatment of diabetes, local anesthetics, dental procedures and vaccinations. Needle free technology is not just an alternative for needle phobia. INJEX technological efficacy will benefit providers in delivering superior patient centric care. Giving patients a pain free alternative without mitigating efficacy makes sense.' Mr. Alexander Novgorodov, General Manager, MEDICI Ltd.
'Simultaneously the innovative Poring-Method with the SHIREEN Beauty Kit also offers huge market potential for the booming beauty market in Russia.' Mr. Novgorodov
'The SHIREEN Poring-Method combined with the proprietary SHIREEN Fluid helps to restore a profound long-lasting smoothing of first superficial wrinkles on the face, neck, décolleté and back of the hands. 'The SHIREEN PoreJet utilizes for the Poring-Method essential Poring-Tip, allowing SHIREEN Fluid to be evenly sprayed through the pores and the outer skin layers. Our new technology offers a pain-free, effective and long lasting effect.' Andy Rösch, CEO of INJEX Pharma AG.
'The breakthrough SHIREEN Beauty-Kit will assist Russian service providers and their patients in meeting the demand for the expanding beauty space. It's an innovative painless application for people wanting to restore a younger, fresher and more beautiful appearance without pain. Other benefits include the avoidance of time-consuming treatments and unnecessary potential risks associated with traditional use of needles. We are confident this technology is needed and its time has arrived. Our initial estimates are quite conservative and we have planned accordingly for upward revisions in the short term to meet demand.' Mr. Novgorodov, MEDICI Ltd.
Contact:
Andy Rösch
CEO
INJEX Pharma AG
Buckower Damm 114
12349 Berlin
Tel.: 0049-30-53096768
andy.roesch@injex.com
www.injex.com
Sylwin Grinman
Managing Director
INJEX Pharma USA
1922 NE 119 RD
North Miami Beach - FL - 33181
USA
Tel.: +1 786 512 196 3
sylwin@injex.com
Preliminary figures first Half of 2012 and Preliminary figures third quarter
October 2012
http://www.injex.com/investor-timetable
www.injexsoftshot.com - new website by American Healthcare Product Incorporated, & Injex with lots of information, reports of scientific studies about Injex as well as an online-shop.
Cheers and have a good day,
Neo (aka tnzs)
Shireen-Beauty => new website!
German only so far, but anyway here we go:
http://www.beauty-shireen.com
Cheers and have a good day,
Neo (aka tnzs)
Thanks for the updates.
Keep them coming...
regards
I don't know if there will be ADR or something like that!
The next step in the USA will be the NASDAQ listing. (october or november)
I also don't know how the advertisement will look like.
I will let myself be surprised. :)
Thanks.
If this is the same Sammy Sosa, they should be very well covered on the advertising part.
Any idea when they plan to become public in the US and how? ( ADR or reverse larger)?
@Rymankoly
The Manager of 21 MEDICAL TECHNOLOGIES, LLC is Samuel Sosa!
http://ccfcorp.dos.state.fl.us/scripts/cordet.exe?action=DETFIL&inq_doc_number=L12000110027&inq_came_from=NAMFWD&cor_web_names_seq_number=0000&names_name_ind=&names_cor_number=&names_name_seq=&names_name_ind=&names_comp_name=21MEDICALTECHNOLOGIES&names_filing_type=
You know Sammy Sosa? ;)
This should also clear the question of the advertising character and the budget.
Interesting.
Since this is the cosmetic market, they will have to go to full mode advertising, who will provide the budget and what medium will they use ?
INJEX Pharma AG signs exclusive Distribution Agreement for USA / Minimum Purchase of 70,000 INJEX30 Systems and 25,000 SHIREEN Beauty Kits in the first year
INJEX Pharma AG / Key word(s): Contract
04.09.2012 / 15:37
INJEX Pharma AG signs exclusive Distribution Agreement for USA / Minimum Purchase of 70,000 INJEX30 Systems and 25,000 SHIREEN Beauty Kits in the first year
INJEX Pharma AG ISIN: DE000A0STYL7
Berlin, 04 September 2012
Berlin - Newly founded '21 Medical Technologies LLC.,' (21 MT) located in Fort Lauderdale, Florida, will exclusively market and distribute INJEX30 Systems in the United States. INJEX30 syringes without a needle may be used in multiple medical, cosmetic and anesthetic applications and marketed via traditional pharmaceutical and emerging life science modalities. INJEX30 targeted disease states and delivery systems include diabetes, local and dental anesthetics, allergy and fertility treatments, vaccinations, erectile dysfunction and growth hormones. '21 MT' is a perfect partner in the US and it's an exciting time for INJEX Pharma AG as we continue to execute on our global mission while simultaneously introducing the SHIREEN Beauty Kit utilizing a 'Poring method' in the United States.' Andy Rösch, CEO INJEX Pharma AG.
The signed distributor agreement includes a minimum volume of 70,000 INJEX30 Systems, 25,000 SHIREEN Beauty Kits and 300,000 SHIREEN Fluid Units. The First shipment will commence during the month of September.
'Product launches in the United States must be carefully orchestrated across many modalities including direct to the consumer. The United States' healthcare industry appears to be in early stages of its transformation which presents an opportune time to align our innovative technology with a 'High profile personality.' '21 MT' has the ability to raise immediate awareness for both INJEX30 Systems and SHIREEN Beauty Kits through its media reach and seasoned team of professionals. We look forward to working closely with '21 MT' as they prepare to deploy significant resources across modalities. This multi-faceted approach will be necessary to build brand awareness with an emphasis on 'service excellence.' This agreement is a 'Home run' for the end users who will benefit from a syringe delivery system without a needle.' Sylwin Grinman, Director International Sales and Marketing at INJEX Pharma AG.
'We are excited to begin marketing our innovative 'Poring method' with SHIREEN Beauty Kits in the world's biggest beauty market. '21 MT' was founded with an appreciation for challenges when dealing with big markets and we are comfortable '21 MT' will exceed distribution expectations and establish new benchmarks for 'service excellence' in this industry. We will be increasing our production capacities in the short-term and developing necessary logistical contingencies to meet future demand. '21 MT' will consummate this agreement in the days ahead, with payments on the way, triggering exclusivity, as terms for initial shipments are met. Shortly thereafter, we expect to conduct a press conference with 21 Medical Technologies LLC, elaborating on our vision, steps for executing in the US and defining details related to this agreement.' Andy Rösch, CEO INJEX Pharma AG.
Contact:
Andy Rösch
CEO
INJEX Pharma AG
Buckower Damm 114
12349 Berlin
Tel.: +49-3053096768
andy.roesch@injex.com
www.injex.com
Sylwin Grinman
Managing Director
INJEX Pharma USA
1922 NE 119 RD
North Miami Beach - FL - 33181
USA
Tel.: +1-7865121963
sylwin@injex.com
End of Corporate News
source:
http://www.dgap.de/news/corporate/injex-pharma-signs-exclusive-distribution-agreement-for-usa-minimum-purchase-injex-systems-and-shireen-beauty-kits-the-first-year_42269_731650.htm
blackleguan
We are in 100% agreement.
Both companies focus their efforts in totally different fields.
Antares is pushing the in-house programs MTX and QST plus the injectors with TEVA (and of course the gel programs and Pfizer deal).
None of the above programs compete with injex, which their current focus is the cosmetic market (which also has high competition from many other companies and different solution).
look to me like the other poster is trying to lay the ground for stock promotion in the future, but lack the understanding of the competition, so he keep coming to the ATRS board, where the only common thing is a needle free injector.
(And i know some engine manufacturers who got needle free injectors.... :o))
Good luck to you.
Regards
Ryman
In my opinion there ist no real competition between injex and antares.
Only the other User was talking about that.
Antares has much more in the pipeline and other fields like injex.
The only overlapping thing is the needle free system. Antares was the developer of PharmaJet? I can't remember the right name of the system right now. And that's all...
I think the main product of Injex will be the needle free Shireen poring method in the Beauty Market.
In October or November there will be the first sales figures... until that everything is speculation ;)
I was also thinking about an investment in Antares, but the takeover rumors are making me skeptic at the moment. Maybe in a few months...
best regards
blackleguan
And this is the company they signed disribution agreement with (look at the bottom):
http://www.unisealgloves.com/
(American Healthcare Products Inc.)
Can you show me where the compete with Antares ???
Hey, I will buy them and wait patiently for the pump and dump.
If they already pumping it before the listing, I'm sure they will hire a good penny promoter to do the job, so i will join you for a short ride.
but for competitors you need to look in the cosmetic market, Antares focus is totally different field.
@Rymankoly
No they aren't...
Jim Fukushima was Owner and CEO at this point!
Now Injex is back in Germany. In the Year 2000 the Market wasn't big enough to establish the needle free system.
But now in 2012 some people of the team from 2000 (with the special know-how) are back to place Injex succesfully on the market.
With the innovation of the Shireen system in the Beauty market Injex has a good chance to establish on the market...
We will see...
Wait ........ you're going to still look around what goes here soon ............
New York investment houses give the recommendation to a NASDAQ listing.
since then, the antares perform hide ............
Followers
|
1
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
78
|
Created
|
05/29/12
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |